UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 18, 2019

ASHLAND GLOBAL HOLDINGS INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

333-211719 (Commission File Number) 81-2587835 (I.R.S. Employer Identification No.)

50 E. RiverCenter Boulevard

Covington, Kentucky 41011

Registrant's telephone number, including area code (859) 815-3333

	e appropriate box below if the Form 8-K fil wing provisions:	ing is intended to simultaneous	sly satisfy the filing obligation of the registrant under any of								
	Written communications pursuant to Rule	425 under the Securities Act (17 CFR 230.425)								
	Soliciting material pursuant to Rule 14a-1	2 under the Exchange Act (17	CFR 240.14a-12)								
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))										
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))										
	by check mark whether the registrant is an or Rule 12b-2 of the Securities Exchange A	0 00 1 1	defined in Rule 405 of the Securities Act of 1933 (17 CFR).								
Emerging	g growth company $\ \square$										
	erging growth company, indicate by check new or revised financial accounting standar	_	tted not to use the extended transition period for complying n 13(a) of the Exchange Act. \square								
Securitie	s registered pursuant to Section 12(b) of the	Act:									
	Title of each class	Trading Symbol(s)	Name of each exchange on which registered								
Common	Stock (par value \$.01)	ASH	NYSE								

Item 2.02. Results of Operations and Financial Condition

On November 18, 2019, Ashland Global Holdings Inc. ("Ashland") announced preliminary fourth quarter results, which are discussed in more detail in the news release (the "News Release") attached to this Current Report on Form 8-K ("Form 8-K") as Exhibit 99.1, which is incorporated herein by reference into this Item 2.02.

Item 7.01. Regulation FD Disclosure

On November 18, 2019, Ashland will make available the News Release on the "Investor Center" section of Ashland's website located at http://investor.ashland.com.

Item 9.01. Financial Statements and Exhibits

- (d) Exhibits
- 99.1 News Release dated November 18, 2019.
- 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).

In connection with the disclosures set forth in Items 2.02 and 7.01 above, the information in this Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in this Form 8-K, including the exhibit, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing. This Form 8-K will not be deemed an admission as to the materiality of any information in this Form 8-K that is required to be disclosed solely by Regulation FD.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ASHLAND GLOBAL HOLDINGS INC.

(Registrant)

November 18, 2019

/s/ J. Kevin Willis

J. Kevin Willis Senior Vice President and Chief Financial Officer



News Release

Ashland reports preliminary financial results for fourth quarter of fiscal 2019

- Sales of \$609 million, down 9% versus prior-year quarter
- Net income of \$411 million, or \$6.71 per diluted share
- Income from continuing operations of \$27 million, or \$0.44 per diluted share
- Adjusted income from continuing operations of \$47 million, or \$0.77 per diluted share
- Adjusted EBITDA of \$150 million

COVINGTON, KENTUCKY, November 18, 2019 – Ashland Global Holdings Inc. (NYSE: ASH), a premier global specialty materials company serving customers in a wide range of consumer and industrial markets, today announced preliminary¹ financial results for the fourth quarter of fiscal 2019 ended September 30, 2019.

Sales were \$609 million, down 9 percent versus the prior-year quarter, driven primarily by challenged results at Pharmachem and Personal Care, plus weaker industrial end-market demand within the Specialty Ingredients segment. Income from continuing operations was \$27 million, up \$29 million versus the prior-year quarter, or \$0.44 per diluted share, up \$0.47 from the prior-year quarter. Adjusted income from continuing operations was \$47 million, up 4 percent versus the prior-year quarter, or \$0.77 per diluted share, up 8 percent from the prior-year quarter. Adjusted EBITDA was \$150 million, up 6 percent versus the prior-year quarter due to lower selling, general and administrative ("SG&A") costs primarily resulting from the ongoing cost-reduction program.

In fiscal year 2019, Ashland sales were \$2.5 billion, down 4 percent versus the prior year. Net income was \$505 million, up 343 percent versus the prior year, driven by lower costs from the cost-restructuring program. Operating income margins improved 280 basis points and operating income increased 6 percent when compared to fiscal year 2018.

Bill Wulfsohn, Ashland's chairman and chief executive officer said, "During the quarter and fiscal year, we faced more challenging external conditions than anticipated. Despite these challenges, during fiscal year 2019 we took action to grow adjusted earnings per share by 14 percent, improve adjusted EBITDA margins by 140 basis points and increase adjusted EBITDA by 3 percent. These gains were primarily driven by the impact of Ashland's \$120 million cost-reduction program."

He continued, "In addition, during the quarter we also completed the sale of the Composites business and Marl BDO facility while reducing debt by \$940 million. The sale completes the company's decade-long journey to become a pure-play specialty ingredients company."

Regarding the recently announced leadership transition, Mr. Wulfsohn added, "I thank the Ashland team for their support and hard work which was essential to all we have

accomplished over the past five years. Together we have created a premier specialty ingredients company. Now is the right time for a leadership change and I am confident that Guillermo Novo is the right chairman and CEO to lead the Ashland team on its journey to realize the company's full potential."

Guillermo Novo, current Ashland director and incoming chairman and CEO said, "I am incredibly excited to join the Ashland team and have already been hard at work. I want to thank Bill for all of his support during this transition and I look forward to sharing my initial thoughts on the journey ahead during our conference call with securities analysts tomorrow morning."

Reportable Segment Performance

To aid in the understanding of Ashland's ongoing business performance, the results of Ashland's reportable segments are described below on an adjusted basis. In addition, EBITDA, or adjusted EBITDA, is reconciled to operating income in Table 5, free cash flow and adjusted operating income are reconciled in Table 7, and adjusted income from continuing operations and adjusted diluted earnings per share are reconciled in Table 8 of this news release. These adjusted results are considered non-GAAP financial measures. For a full description of the non-GAAP financial measures used, see the "Use of Non-GAAP Measures" section that further describes these adjustments below.

Specialty Ingredients

Sales were \$579 million, down 9 percent from the prior-year quarter, due to challenged results at Pharmachem and Personal Care, plus weaker industrial end-market demand. Unfavorable foreign currency reduced sales by 1 percent.

Operating income was \$92 million, consistent with the prior-year quarter. Adjusted EBITDA was \$152 million, down 5 percent from the prior-year quarter, as lower sales and gross profit were partially offset by lower SG&A costs.

Intermediates & Solvents

Sales were \$30 million, down 3 percent from the prior-year quarter, due to changing market-demand dynamics.

Operating income was \$6 million, consistent with the prior-year quarter. Adjusted EBITDA was \$9 million, consistent with the prior-year quarter, as lower pricing was offset by favorable raw-material costs.

Unallocated & Other

Unallocated & other expense was \$13 million, compared to \$94 million in the prior-year quarter, primarily due to lower restructuring and environmental expenses. Adjusted unallocated & other expense was \$13 million, compared to \$28 million in the prior-year quarter, primarily due to lower costs from the ongoing cost-reduction program.

Fiscal Year 2019 Results Summary

During fiscal year 2019, Ashland generated sales of \$2.5 billion, down 4 percent compared to the prior year. Strong results in Pharma and consistent results in Coatings and Adhesives were more than offset by the Colgate-Gantrez reformulation within Personal Care, challenges at Pharmachem and general weakness throughout the year in industrial end markets.

Net income was \$505 million compared to \$114 million in the prior fiscal year. Adjusted EBITDA was \$532 million, up from \$515 million in the prior year, driven by lower costs from the cost-restructuring program.

Outlook

Incoming Chairman and CEO Guillermo Novo will provide commentary on the outlook for Ashland during the conference call with securities analysts on Tuesday, November 19, 2019.

Conference Call Webcast

Ashland will host a live webcast of its fourth-quarter conference call with securities analysts at 9 a.m. EST Tuesday, November 19, 2019. The webcast will be accessible through Ashland's website at http://investor.ashland.com and will include a slide presentation. Following the live event, an archived version of the webcast and supporting materials will be available for 12 months.

Use of Non-GAAP Measures

Ashland believes that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes and certain other charges that are highly variable from year to year, EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin provide Ashland's investors with performance measures that reflect the impact to operations from trends in changes in sales, margin and operating expenses, providing a perspective not immediately apparent from net income, operating income, net income margin and operating income margin. The adjustments Ashland makes to derive the non-GAAP measures of EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin exclude items which may cause short-term fluctuations in net income and operating income and which Ashland does not consider to be the fundamental attributes or primary drivers of its business. EBITDA, adjusted EBITDA, EBITDA margin and adjusted EBITDA margin provide disclosure on the same basis as that used by Ashland's management to evaluate financial performance on a consolidated and reportable segment basis and provide consistency in our financial reporting, facilitate internal and external comparisons of Ashland's historical operating performance and its business units and provide continuity to investors for comparability purposes. EBITDA margin and adjusted EBITDA margin are defined as EBITDA and adjusted EBITDA divided by sales for the corresponding period.

Key items, which are set forth on Table 8 of this release, are defined as financial effects from significant transactions that, either by their nature or amount, have caused short-term fluctuations in net income and/or operating income which Ashland does not consider to most accurately reflect Ashland's underlying business performance and trends. Further, Ashland believes that providing supplemental information that excludes the financial effects of these items in the financial results will enhance the investor's ability to compare financial performance between reporting periods.

Tax-specific key items, which are set forth on Table 8 of this release, are defined as financial transactions, tax law changes or other matters that fall within the definition of key items as described above. These items relate solely to tax matters and would only be recorded within the income tax caption of the Statement of Consolidated Income. As with all key items, due to their nature, Ashland does not consider the financial effects of these tax-specific key items on net income to be the most accurate reflection of Ashland's underlying business performance and trends.

The free cash flow metric enables Ashland to provide a better indication of the ongoing cash being generated that is ultimately available for both debt and equity holders as well as other investment opportunities. Unlike cash flow provided by operating activities, free cash flow includes the impact of capital expenditures from continuing operations, providing a more complete picture of cash generation. Free cash flow has certain limitations, including that it does not reflect adjustment for certain non-discretionary cash flows such as mandatory debt repayments. The amount of mandatory versus discretionary expenditures can vary significantly between periods.

Adjusted diluted earnings per share is a performance measure used by Ashland and is defined by Ashland as earnings (loss) from continuing operations, adjusted for identified key items and divided by the number of outstanding diluted shares of common stock. Ashland believes this measure provides investors additional insights into operational performance by providing earnings and diluted earnings per share metrics that exclude the effect of the identified key items and tax specific key items.

About Ashland

Ashland Global Holdings Inc. (NYSE: ASH) is a premier global specialty materials company serving customers in a wide range of consumer and industrial markets, including adhesives, architectural coatings, automotive, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. At Ashland, we are approximately 4,700 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – who thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com to learn more.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "forecasts," "objectives," "may," "will," "should," "plans" and "intends" and the negative of these words or other comparable terminology. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the SEC, news releases and other written and oral communications. These forward-looking statements are based on Ashland's expectations and assumptions, as of the date such statements are made, regarding Ashland's future operating performance and financial condition, as well as the economy and other future events or circumstances. These statements include, but may not be limited to Ashland's assessment on its progress towards becoming a premier specialty materials company; and its expectations regarding its ability to drive sales and earnings growth and realize further cost reductions.

Ashland's expectations and assumptions include, without limitation, internal forecasts and analyses of current and future market conditions and trends, management plans and strategies, operating efficiencies and economic conditions (such as prices, supply and demand, cost of raw materials, and the ability to recover raw-material cost increases through price increases), and risks and uncertainties associated with the following: the program to eliminate certain existing corporate and Specialty Ingredients expenses (including the possibility that such cost eliminations may not occur or may take longer to implement than anticipated), the impact of acquisitions and/or divestitures Ashland has made or may make (including the possibility that Ashland may not realize the anticipated benefits from such transactions); Ashland's substantial indebtedness (including the possibility that such indebtedness and related restrictive covenants may adversely affect Ashland's future cash flows, results of operations, financial condition and its ability to repay debt); severe weather, natural disasters, cyber events and legal proceedings and claims (including product recalls, environmental and asbestos matters); and without limitation, risks and uncertainties affecting Ashland that are described in Ashland's most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland's website at http://investor.ashland.com or on the SEC's website at http://www.sec.gov. Various risks and uncertainties may

cause actual results to differ materially from those stated, projected or implied by any forward-looking statements. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether as a result of new information, future events or otherwise.

¹Financial results are preliminary until Ashland's Form 10-K is filed with the SEC

TM Trademark, Ashland or its subsidiaries, registered in various countries.

FOR FURTHER INFORMATION:

Investor Relations: Seth A. Mrozek +1 (302) 594-5010 samrozek@ashland.com Media Relations: Joy Brock +1 (859) 815-3793 jlbrock@ashland.com

	Three months ended September 30					ear ended otember 30			
		2019	2018		2019			2018	
Sales	\$	609	\$	667	\$	2,493	\$	2,589	
Cost of sales		400		436		1,726		1,726	
GROSS PROFIT		209		231		767	·	863	
Selling, general and administrative expense		109		211		539		692	
Research and development expense		15		17		66		73	
Equity and other income		-		1		4		4	
OPERATING INCOME		85		4		166		102	
Net interest and other expense		26		25		99		102	
Other net periodic benefit income (costs)		(11)		14		5		15	
Net income (loss) on acquisitions and divestitures		1		-		(2)		(4)	
INCOME (LOSS) FROM CONTINUING OPERATIONS				<u></u>					
BEFORE INCOME TAXES		49		(7)		70		11	
Income tax expense (benefit)		22		(5)		46		(8)	
INCOME (LOSS) FROM CONTINUING OPERATIONS		27		(2)		24		19	
Income from discontinued operations (net of income taxes)		384		Ì1		481		95	
NET INCOME	\$	411	\$	9	\$	505	\$	114	
					_				
DILUTED EARNINGS PER SHARE									
Income (loss) from continuing operations	\$	0.44	\$	(0.03)	\$	0.39	\$	0.29	
Income from discontinued operations		6.27		0.18		7.64		1.50	
Net income	\$	6.71	\$	0.15	\$	8.03	\$	1.79	
	<u>*</u>		<u> </u>		÷		÷		
AVERAGE DILUTED COMMON SHARES OUTSTANDING (a)		61		63		63		64	
CALEC									
SALES Specialty Ingredients	\$	579	\$	636	\$	2,382	\$	2,470	
Intermediates and Solvents	Ψ	30	Ψ	31	Ψ	111	Ψ	119	
intermediates and Solvents	\$	609	\$	667	\$	2,493	Φ	2,589	
	Φ	009	Φ	007	Φ	2,493	\$	2,569	
OPERATING INCOME (LOSS)									
Specialty Ingredients	\$	92	\$	92	\$	272	\$	314	
Intermediates and Solvents	Ψ	6	Ψ	6	Ψ	16	Ψ	17	
Unallocated and other		(13)		(94)		(122)		(229)	
Chanocated and other	\$	85	\$	(94) 4	\$	166	\$	102	
	<u>Φ</u>	00	φ	4	Φ	100	Φ	102	

⁽a) As a result of the loss from continuing operations for the three months ending September 30, 2018, the effect of the share-based awards convertible to common shares would be anti-dilutive. In accordance with U.S. GAAP, these shares have been excluded from the diluted earnings per share calculation for this period.

	September 3 20:	
ASSETS		
Current assets	Φ	20 # 204
Cash and cash equivalents	\$ 23	
Accounts receivable	48	
Inventories	59	
Other assets		60
Held for sale		59 240
Total current assets	1,43	33 1,712
Noncurrent assets		
Property, plant and equipment		
Cost	3,16	3,172
Accumulated depreciation	1,58	
Net property, plant and equipment	1,5	
Goodwill	2,29	53 2,304
Intangibles	1,08	
Restricted investments	3:	
Asbestos insurance receivable	15	
Deferred income taxes		23 28
Other assets	4	
Held for sale		- 477
Total noncurrent assets	5,83	
Total Horiculterit assets		0,347
Total assets	\$ 7,25	<u>\$ 8,259</u>
LIABILITIES AND EQUITY		
Current liabilities		
Short-term debt	\$ 16	66 \$ 254
Trade and other payables	33	L3 331
Accrued expenses and other liabilities	2	71 328
Held for sale		7 163
Total current liabilities	75	1,076
Noncurrent liabilities		
Long-term debt	1,50	2,275
Asbestos litigation reserve	55	
Deferred income taxes	20	
Employee benefit obligations		50 156
Other liabilities	45	53 422
Held for sale	-10	<u>-</u> 26
Total noncurrent liabilities	2,92	
Stockholders' equity	3,5	71 3,406
Total liabilities and stockholders' equity	\$ 7,25	<u>\$ 8,259</u>

Excludes changes resulting from operations acquired or sold.

	Three months ended September 30					Year ended September 30				
	2	2019	20	18		2019		2018		
CASH FLOWS PROVIDED (USED) BY OPERATING ACTIVITIES FROM CONTINUING OPERATIONS										
Net income	\$	411	\$	9	\$	505	\$	114		
Income from discontinued operations (net of taxes)	•	(384)		(11)		(481)	·	(95)		
Adjustments to reconcile income from continuing operations to										
cash flows from operating activities		64		60		200		077		
Depreciation and amortization Original issue discount and debt issuance cost amortization		64 7		68 2		289 13		277 8		
Deferred income taxes		19		(97)		20		(100)		
Equity income from affiliates		-		(1)		-		(200)		
Distributions from equity affiliates		-		-		-		1		
Stock based compensation expense		5		7		21		27		
Excess tax benefit on stock based compensation		9		- (4)		11		4		
Loss (income) from restricted investments Net (income) loss on acquisitions and divestitures		(7)		(4)		(17)		(14) 1		
Impairments				16		8		16		
Pension contributions		(1)		(1)		(5)		(9)		
Loss (gain) on pension and other postretirement plan remeasurements		Ì1 [′]		(14)		(7)		(14)		
Change in operating assets and liabilities (a)		1		174		(129)		25		
Total cash flows provided (used) by operating activities from continuing operations		135		148		228		241		
CASH FLOWS PROVIDED (USED) BY INVESTING ACTIVITIES FROM CONTINUING OPERATIONS										
Additions to property, plant and equipment		(52)		(69)		(154)		(157)		
Proceeds from disposal of property, plant and equipment		(32)		3		9		(157)		
Purchase of operations - net of cash acquired				-		(2)		(11)		
Proceeds from sale or restructuring of operations		-		5		-		` 6		
Life insurance payments		-		-		-		(37)		
Net purchase of funds restricted for specific transactions		(4)		-		(7)		(10)		
Reimbursements from restricted investments		7		8		32		33		
Proceeds from sale of securities Purchases of securities		192 (192)		8		348 (348)		26 (26)		
Proceeds from the settlement of derivative instruments		(192)		(8)		(346)		(20)		
Payments for the settlement of derivative instruments		-		(1)		(2)		(3)		
Total cash flows provided (used) by investing activities from continuing operations		(43)		(54)		(118)		(174)		
CASH FLOWS PROVIDED (USED) BY FINANCING ACTIVITIES		` ,		,		, ,		` ,		
FROM CONTINUING OPERATIONS										
Proceeds from issuance of long-term debt		(700)		(470)		(707)		(011)		
Repayment of long-term debt Premium on long-term debt repayment		(788)		(176)		(797)		(311)		
Proceeds from (repayment of) short-term debt		(161)		172		(78)		15		
Repurchase of common stock		(101)				(200)		-		
Debt issuance costs		-		-		-		(2)		
Cash dividends paid		(16)		(16)		(64)		(60)		
Stock based compensation employee withholding taxes paid in cash		(2)		(1)		(10)		(10)		
Total cash flows provided (used) by financing activities from continuing operations		(967)		(21)		(1,149)		(368)		
CASH PROVIDED (USED) BY CONTINUING OPERATIONS		(875)		73		(1,039)		(301)		
Cash provided (used) by discontinued operations Operating cash flows		14		55		13		56		
Investing cash flows		961		(14)		967		(28)		
Financing cash flows		001		(= .)		00.		(20)		
Effect of currency exchange rate changes on cash and cash equivalents				(2)		(3)		1		
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		100		112		(62)		(272)		
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD		132		182		294		566		
CASH AND CASH EQUIVALENTS - END OF PERIOD	\$	232	\$	294	\$	232	\$	294		
	<u> </u>			_						
DEPRECIATION AND AMORTIZATION			_		_					
Specialty Ingredients	\$	60	\$	64	\$	273	\$	252		
Intermediates and Solvents Unallocated and other		3		3 1		13 3		14 11		
Chambeated and Other		1 64	\$	<u>1</u> 68	\$	289	\$	<u>11</u> 277		
ADDITIONS TO PROPERTY, PLANT AND EQUIPMENT	Ψ	04	Ψ	00	Ψ	203	Ψ	211		
Specialty Ingredients	\$	45	\$	62	\$	137	\$	138		
Intermediates and Solvents	Ψ	3	Ψ	2	•	7	Ψ	5		
Unallocated and other		4		5	_	10	_	14		
	\$	52	\$	69	\$	154	\$	157		

	•	Three months ended September 30				Year ended September 30			
	2019		2	2018	2019			2018	
SPECIALTY INGREDIENTS									
Sales per shipping day	\$	9.0	\$	10.1	\$	9.4	\$	9.8	
Metric tons sold (thousands)		80.0		84.6		317.2		324.7	
Gross profit as a percent of sales (a)		34.7%		35.1%		31.1%		33.8%	
INTERMEDIATES AND SOLVENTS									
Sales per shipping day	\$	0.5	\$	0.5	\$	0.4	\$	0.5	
Metric tons sold (thousands)		9.9		9.4		35.3		37.5	
Gross profit as a percent of sales (a)		28.8%		26.3%		23.1%		23.0%	

⁽a) Gross profit as a percent of sales is defined as sales, less cost of sales divided by sales.

	Three months end						
	 Septen	nber:	30				
Adjusted EBITDA - Ashland Global Holdings Inc.	 2019		2018				
Net income	\$ 411	\$	9				
Income tax expense	22		(5)				
Net interest and other expense (income)	26		25				
Depreciation and amortization (a)	 64		67				
EBITDA	523		96				
Income from discontinued operations (net of taxes)	(384)		(11)				
Loss (gain) on pension and other postretirement plan remeasurements	11		(14)				
Net (income) loss on divestitures key items (see Table 6)	-		-				
Operating key items (see Table 6)	 		71				
Adjusted EBITDA	\$ 150	\$	142				
	 	-					
Adjusted EBITDA - Specialty Ingredients							
Operating income	\$ 92	\$	92				
Add:							
Depreciation and amortization (a)	60		63				
Operating key items (see Table 6)	 		5				
Adjusted EBITDA	\$ 152	\$	160				
	 	-					
Adjusted EBITDA - Intermediates and Solvents							
Operating income	\$ 6	\$	6				
Add:							
Depreciation and amortization	3		3				
Operating key items (see Table 6)	-		-				
Adjusted EBITDA	\$ 9	\$	9				

⁽a) Depreciation and amortization excludes accelerated depreciation of \$1 million for Specialty Ingredients for the three months ended September 30, 2018 which is included as a key item within this table.

Ashland Global Holdings Inc. and Consolidated Subsidiaries SEGMENT COMPONENTS OF KEY ITEMS FOR APPLICABLE INCOME STATEMENT CAPTIONS

(In millions - preliminary and unaudited)

	Three Months Ended September 30, 2019								
		cialty	Intermed	ates	Un	allocated		T	
OPERATING INCOME (LOSS)	Ingre	dients	and Solv	ents	8	& Other	_	Total	
Operating key items:									
Restructuring, separation and other costs Proxy costs	\$	-	\$	-	\$	(1) 1	\$	(1) 1	
All other operating income (loss)		92		6		(13)		85	
Operating income (loss)		92		6		(13)		85	
NET INTEREST AND OTHER EXPENSE									
Key items						1		1	
All other net interest and other expense						25 26	_	25 26	
NET INCOME (LOSS) ON DIVESTITURES						1		1	
NET INCOME (E033) ON DIVESTITORES						_		-	
OTHER NET PERIODIC BENEFIT INCOME (COSTS) Key items						(11)		(11)	
All other net periodic benefit income						(II) -		<u>-</u>	
INCOME TAX EXPENSE (BENEFIT)						(11)		(11)	
Tax effect of key items (a)						(3)		(3)	
Tax specific key items (b)						11		11	
All other income tax expense (benefit)						14 22		14 22	
INCOME (LOSS) FROM CONTINUING OPERATIONS	\$	92	\$	6	\$	(71)	\$	27	
			Three Mon	ths Ender	l Sentemi	ber 30, 2018			
	Spe	cialty	Intermed			allocated			
OPERATING INCOME (LOCC)	Ingre	dients	and Solv	ents	8	& Other		Total	
OPERATING INCOME (LOSS) Operating key items:									
Restructuring, separation and other costs	\$	(3)	\$	-	\$	(47)	\$	(50)	
Asset impairments Tax indemnity expense		(2)		-		(14) (5)		(16) (5)	
All other operating income (loss)		97		6		(28)		75	
Operating income (loss)		92		6		(94)		4	
NET INTEREST AND OTHER EXPENSE						25		25	
NET INCOME (LOSS) ON DIVESTITURES						-		-	
OTHER NET PERIODIC BENEFIT INCOME (COSTS)						4.4		4.4	
Key items All other net periodic benefit costs						14 		14 	
INCOME TAX EXPENSE (BENEFIT)						14		14	
Tax effect of key items (a)						(9)		(9)	
Tax specific key items (b) All other income tax expense (benefit)						(1) 5		(1) 5	
						(5)		<u>(5</u>)	

INCOME (LOSS) FROM CONTINUING OPERATIONS

92

(100)

Represents the tax effect of the key items that are previously identified above.
Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. See Table 8 for additional information.

	Three months ended September 30					Year ended September 30				
Free cash flows (a)		2019		2018		2019		2018		
Total cash flows used by operating activities from continuing operations	\$	135	\$	148	\$	228	\$	241		
Adjustments: Additions to property, plant and equipment		(52)		(69)		(154)		(157)		
Free cash flows (a)	\$	83	\$	79	\$	74	\$	84		

⁽a) Free cash flow is defined as cash flows provided (used) by operating activities less additions to property, plant and equipment and other items Ashland has deemed non-operational (if applicable).

Three m					Year ended				
		Septem	ber 30		September 30				
Adjusted operating income (loss)	2019		2018		2019		2	2018	
Operating income (loss) (as reported)	\$	85	\$	4	\$	166	\$	102	
Key items, before tax:									
Restructuring, separation and other costs		1		50		90		91	
Proxy costs		(1)		-		4		-	
Asset impairments		-		16		-		16	
Tax indemnity expense		-		5		6		5	
Environmental reserve adjustments		-		-		15		43	
Legal settlement/reserve		-		-		-		(5)	
Unplanned plant shutdowns		-		-		2		-	
Inventory fair value adjustment								<u>-</u>	
Adjusted operating income (non-GAAP)	\$	85	\$	75	\$	283	\$	252	

RECONCILIATION OF CERTAIN NON-GAAP DATA

(In millions except per share data - preliminary and unaudited)

	Three months ended September 30					Year ended September 30			
	20	19	2018		2019		2018		
Income (loss) from continuing operations (as reported)	\$	27	\$	(2)	\$ 24	\$	19		
Key items, before tax:									
Restructuring, separation and other costs		1		50	90		91		
Proxy costs Proxy costs		(1)		-	4		-		
Tax indemnity expense		-		5	6		5		
Loss (gain) on pension and other postretirement plan remeasurements		11		(14)	(7)		(14)		
Environmental reserve adjustments		-		-	15		44		
Legal settlement		-		-	-		(5)		
Unplanned plant shutdowns		-		-	2		-		
Unrealized (gain) loss on securities		(5)		-	(7)		-		
Asset Impairments		-		16	-		16		
Debt refinancing costs		6		-	6		1		
Net loss on acquisitions and divestitures		<u>-</u>		<u> </u>	3		2		
Key items, before tax	·	12		57	112		140		
Tax effect of key items (a)		(3)		(9)	(14)		(30)		
Key items, after tax	·	9		48	98		110		
Tax specific key items:									
Deferred tax rate changes		-		(9)	2		(139)		
One-time transition tax		-		(15)	28		128		
Uncertain tax positions		2		(24)	(6)		(26)		
Restructuring and separation activity		13		36	12		36		
Other tax reform related activity		(1)		11	(1)		11		
Other		(3)					<u>-</u>		
Tax specific key items (b)		11		(1)	35		10		
Total key items	·	20		47	133		120		
Adjusted income from continuing operations (non-GAAP)	\$	47	\$	45	\$ 157	\$	139		

	Three months ended September 30					Year ended September 30			
		2019		2018		2019		2018	
Diluted EPS from continuing operations (as reported)	\$	0.44	\$	(0.03)	\$	0.39	\$	0.29	
Key items, before tax:									
Restructuring, separation and other costs		0.01		0.78		1.42		1.43	
Proxy costs		(0.01)		-		0.07		-	
Tax indemnity expense		-		0.08		0.10		0.08	
Loss (gain) on pension and other postretirement plan remeasurements		0.18		(0.22)		(0.11)		(0.22)	
Environmental reserve adjustments		-		-		0.24		0.68	
Legal settlement		-		-		-		(0.07)	
Unplanned plant shutdowns		-		-		0.03		-	
Unrealized (gain) loss on securities		(0.07)		-		(0.11)		-	
Asset Impairments		-		0.25		-		0.25	
Debt refinancing costs		0.09		-		0.09		0.02	
Net loss on acquisitions and divestitures				<u>-</u>		0.05		0.04	
Key items, before tax		0.20		0.89		1.78		2.21	
Tax effect of key items (a)		(0.05)		(0.13)		(0.22)		(0.47)	
Key items, after tax		0.15		0.76		1.56		1.74	
Tax specific key items:									
Deferred tax rate changes		-		(0.14)		0.03		(2.18)	
One-time transition tax		-		(0.22)		0.44		2.00	
Uncertain tax positions		0.03		(0.39)		(0.09)		(0.39)	
Restructuring and separation activity		0.21		0.56		0.19		0.56	
Other tax reform related activity		(0.02)		0.17		(0.02)		0.17	
Other		(0.04)		_		_		_	
Tax specific key items (b)		0.18		(0.02)		0.55		0.16	
Total key items		0.33		0.74		2.11		1.90	
Adjusted diluted EPS from continuing operations (non-GAAP)	\$	0.77	\$	0.71	\$	2.50	\$	2.19	

- Represents the tax effect of the key items that are previously identified above.
- Represents key items resulting from tax specific financial transactions, tax law changes or other matters that fall within the definition of tax specific key items. These tax specific key items included the following:
 - Deferred tax rate changes: Includes the impact from the remeasurement of Ashland's domestic deferred tax balances resulting from the enactment of the Tax Cuts and Jobs Act (Tax Act) as well as the impact from rate changes for other jurisdictions.
 - One-time transition tax: Includes the one-time transition tax expense resulting from the enactment of the Tax Act.
 - Uncertain tax positions: Includes the impact from the settlement of uncertain tax positions with various tax authorities.
 - Restructuring and separation activity: Includes the impact from company-wide restructuring activities. These adjustments related to various tax impacts including state tax costs, foreign tax costs and other tax account adjustments.

 Other tax reform: Includes the impact of other items related to the Tax Act and other tax law changes enacted during 2018 and 2019.

Year Ended

RECONCILIATION OF CERTAIN NON-GAAP DATA

(In millions - preliminary and unaudited)

	September 30					
		2019		2018		
Net income (loss)	\$	505	\$	114		
Income tax expense (benefit)		46		(8)		
Net interest and other financing expense		99		102		
Depreciation and amortization (a)		250		263		
EBITDA		900		471		
Income from discontinued operations (net of taxes)		(481)		(95)		
Key items included in EBITDA:						
Restructuring, separation and other costs (b)		51		77		
Proxy costs		4		-		
Accelerated depreciation		39		14		
Environmental reserve adjustments		15		44		
Asset impairments		-		16		
Tax indemnity expense		6		5		
Net loss on acquisitions and divestitures (c)		3		2		
Loss (gain) on pension and other postretirement plan remeasurements		(7)		(14)		
Legal settlement/reserve		-		(5)		
Unplanned plant shutdowns		2				
Total key items included in EBITDA		113		139		
Adjusted EBITDA (d)	\$	532	\$	515		

Excludes \$39 million and \$14 million of accelerated depreciation during 2019 and 2018, respectively.

⁽a) (b) (c) (d) Includes impairments of \$8 million during 2019.

Excludes expense of \$3 million and \$2 million during 2019 and 2018, respectively, related to ongoing adjustments of previous divestiture transactions.

Includes \$9 million and \$8 million during 2019 and 2018, respectively, of net period pension and other postretirement costs (income) recognized ratably throughout the fiscal